stockrowargenex SE
ARGX Healthcare Biotechnology
argenex SE’s revenue for fiscal 2025 (year ended December 2025) was $4.2 billion, up 88.6% from fiscal 2024.
- Revenue
- +52.1%
- EPS
- +43.9%
- Free cash flow
- +537.5%
Quarter to September 2026, against a year earlier
Follow ARGX
Alert me
argenex SE (ARGX) EPS (diluted)
argenex SE's EPS (diluted) for fiscal 2025 was $19.57, up 53.1% from $12.78 in fiscal 2024. Over the twelve months to 30 September 2026 it was $28.66. Over the past ten years it has ranged from −$13.30 (fiscal 2020) to $19.57 (fiscal 2025) — the current reading is the highest in ten years. EPS (diluted) has risen for 3 consecutive fiscal years. argenex SE ranks 6th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $19.57 | 53.13% |
| FY2024 | $12.78 | — |
| FY2023 | −$5.16 | — |
| FY2022 | −$13.05 | — |
| FY2021 | −$7.99 | — |
| FY2020 | −$13.30 | — |
| FY2019 | −$4.73 | — |
| FY2018 | −$2.35 | — |
| FY2017 | −$1.40 | — |
| FY2016 | −$1.26 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $7.80 | 6.56% |
| Jun 2026 | $7.32 | 32.61% |
| Mar 2026 | $5.52 | (31.17%) |
| Dec 2025 | $8.02 | 54.83% |
| 25 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| REGN Regeneron Pharmaceuticals, Inc. compare | $45.29 |
| ARGX argenex SE | $28.66 |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $5.68 |
| INCY Incyte Corporation compare | $1.88 |
| RPRX Royalty Pharma PLC compare | $1.40 |
| GMAB Genmab A/S Sponsored ADR compare | $1.27 |
| ROIV Roivant Sciences Ltd. compare | −$0.53 |
| MRNA Moderna, Inc. compare | −$7.99 |
| RVMD Revolution Medicines, Inc. compare | −$9.11 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on ARGX
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement